Treatment for polycystic ovary syndrome: a critical appraisal of treatment options

References

• Diamanti-Kandarakis E, Kouli C, Bergiele A et al. A survey of polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profiles. J. Clin. Endocrinol. Metab.84, 4006–4011 (1999).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA Polycystic ovary syndrome. N. Engl. J. Med.352, 1223–1236 (2005).
   PubMed Web of Science ®Google Scholar
• de Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril.83, 1454–1460 (2005).
   Google Scholar
• Rotterdam ESHRE/ASRM-sponsored Polycystic Ovary Syndrome Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril.81, 19–25 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab.91, 4237–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Azziz R. The evaluation and management of hirsutism. Obstet. Gynecol.101, 995–1007 (2003).
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinylestradiol and cyproterone acetate on endocrine clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod.16, 36–44 (2001).
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knockenhauser ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab.89, 453–462 (2004).
   PubMed Web of Science ®Google Scholar
• Porcile A, Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil. Steril.55, 877–881 (1991).
   PubMed Web of Science ®Google Scholar
• Nader S. Chronic treatment of polycystic ovary syndrome: oral contraceptive pills In: Insulin Resistance and Polycystic Ovarian Syndrome. Diamanti-Kandarakis E, Nestler JE, Panidis D, Pasquale R (Eds). Humana Press, NJ, USA 29, 397–414 (2007).
   Google Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod.22, 317–322 (2007).
   PubMed Web of Science ®Google Scholar
• Mowsowicz I, Wright F, Vincens M et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J. Steroid Biochem.20, 757–761 (1984).
   PubMedGoogle Scholar
• Lobo R, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil. Steril.43, 200–205 (1985).
   PubMed Web of Science ®Google Scholar
• Unluhizara K, Kelestimur F. In: Insulin Resistance and Polycystic Ovarian Syndrome. Diamanti-Kandarakis E, Nestler JE, Panidis D, Pasquale R (Eds). Humana Press, Totowa, NJ, USA 28, 387–396 (2007).
   Google Scholar
• Venturoli S, Marescalchi O, Colombo FM et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone–estrogen regimen in treatment of hirsutism. J. Clin. Endocrinol. Metab.84, 1304–1310 (1999).
   PubMed Web of Science ®Google Scholar
• Erenus M, Gurbuz O Durmusoglu F, Demircay Z, Pelcin S. Comparison of efficacy of spironolactone versus flutamide in treatment of hirsutism. Fertil. Steril.61, 613–616 (1994).
   PubMed Web of Science ®Google Scholar
• Calaf J, Loper E, Millet A et al. Long-term efficacy and tolerability of flutamide combined with oral contraceptives in moderate to severe hirsutism: a 12 month double blind parallel clinical trial. J. Clin. Endocrinol. Metab.92, 3446–3452 (2007).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Jamarillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low dose flutamide in hyperandrogenic girls and young women. Hum. Reprod.20, 833–836 (2005).
   Google Scholar
• Dallob AL, Sadick NS, Unger W et al. The effect of finasteride, a 5 αreductase inhibitor on scalp skin, testosterone and dihydrotestosterone concentrations I patients with male pattern baldness. J. Clin. Endocrinol. Metab.79, 703–706 (1994).
   PubMed Web of Science ®Google Scholar
• Bayram F, Muderris I I, Sahin Y, Kelestimur F. Finasteride treatment for one year in 35 hirsute patients. Exp. Clin. Endocrinol. Diab.107, 195–197 (1999).
   PubMedGoogle Scholar
• Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride and spironolactone to treat idiopathic hirsutism. Fertil. Steril.79, 942–94 (2003).
   PubMed Web of Science ®Google Scholar
• Erenus M, Yucelten , Durmusoglu F, Gurbuz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil. Steril.68, 1000–1003 (1997).
   PubMed Web of Science ®Google Scholar
• Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil. Steril.75, 496–500 (2001).
   PubMed Web of Science ®Google Scholar
• Sahin Y, Bayram F, Kelestimur F, Muderris I. Comparison of cyproterone acetate plus ethinylestradiol and finasteride in the treatment of hirsutism. J. Endocrinol. Invest.21, 348–352 (1998).
   PubMed Web of Science ®Google Scholar
• Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome. Clin. Endocrinol.62, 644–649 (2005).
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobe RA. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs duration of remission. Fertil. Steril.69, 1075–1079 (1998).
   PubMed Web of Science ®Google Scholar
• Spritzer P, Billaud L, Thalabard JC et al. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J. Clin. Endocrinol. Metab.70, 642–646 (1990).
   PubMed Web of Science ®Google Scholar
• Azziz R, Ochoa TM, Bradley L Jr, Potter HT, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J. Clin. Endocrinol. Metab.80, 3406–3411 (1995).
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Gonadotropin releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in longer remission. Hum. Reprod.12, 663–666 (1997).
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Karakoc A, Toruner FB et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol.21(3), 154–160 (2005).
   PubMed Web of Science ®Google Scholar
• Costello M, Shrestha B, Eden J, Sjoblom P, Johnson M. Insulin sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease and endometrial carcinoma in polycystic ovary syndrome. Cochrane Database of Syst. Rev.1, CD0005552 (2007).
   Google Scholar
• Azziz R, Ehrman D, Legro R et al. Troglitazone improves ovulation and hirsutism in polycystic ovary syndrome: a multi-center, double-blind placebo-controlled trial. J. Clin. Endocrinol. Metab.86, 1626–32 (2001).
   PubMed Web of Science ®Google Scholar
• Olsen EA. Methods of hair removal. J. Am. Acad. Dermatol.40, 143–155 (1999).
   PubMed Web of Science ®Google Scholar
• Haedersdal M, Wulf HC. Evidence-based review of hair removal using laser and light sources. J. Eur. Acad. Dermatol. Venereol.20, 9–20 (2006).
   PubMed Web of Science ®Google Scholar
• Malhotra B, Noveck R, Behr D, Palmisano M. Percutaneous absorption and pharmacokinetics of eflornithine HCL 13.9% cream in women with unwanted facial hair. J. Clin. Pharmacol.41, 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab.93, 1105–1120 (2008).
   PubMed Web of Science ®Google Scholar
• Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception73, 23–29 (2006).
   PubMed Web of Science ®Google Scholar
• James WD. Acne. N. Engl. J. Med.352, 1463–1472 (2005).
   PubMed Web of Science ®Google Scholar
• Shapiro J. Hair loss in women. N. Engl. J. Med.357, 1620–1630 (2007).
   PubMed Web of Science ®Google Scholar
• Vigil P, Contreras P, Alvarado JL, Godoy A, Salgado A, Cortes ME. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum. Reprod.22(11), 2974–2980 (2007).
   PubMed Web of Science ®Google Scholar
• Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purpose and pitfalls. Obstet. Gynecol. Survey59, 141–154 (2004).
   PubMed Web of Science ®Google Scholar
• Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod.18(11), 2289–2293 (2003).
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanisms and implications for atherogenesis. Endocr. Rev.18, 774–800 (1997).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med.111, 607–613 (2001).
   PubMed Web of Science ®Google Scholar
• Third report of the National Cholesterol Education Program. Expert panel on the detection, evaluation and treatment of high blood cholesterol in adults. Final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Talbot EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol.20, 2414–2421 (2000).
   Google Scholar
• Vryonidou A, Papatheodorou A, Tauridou A et al. Association of hyperandrogenism and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 2740–2746 (2005).
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum. Reprod.22, 3197–3203 (2007).
   PubMed Web of Science ®Google Scholar
• Christian R, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzparick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.88, 2562–2568 (2003).
   PubMed Web of Science ®Google Scholar
• Wynn V, Doar JWH. Some effects of oral contraceptives on carbohydrate metabolism. Lancet7624(2), 761–765 (1969).
   Google Scholar
• Baillargeon JP, McClisk DK, Essah PA, Nestler J. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab.90, 3863–3870 (2005).
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Jandrain BJ, Humblet DMP, Jaminet CB, Gaspard UJ, Lefebvre PJ. Effects of one year treatment with low-dose combined oral contraceptives containing ethinylestradiol and cyproterone acetate on glucose and insulin metabolism. Fertil. Steril.59, 797–802 (1993).
   PubMed Web of Science ®Google Scholar
• Perseghin G, Scifo G, Pagliato E et al. Gender factors affecting fatty acids-induced insulin resistance in non-obese humans: effects of oral steroidal contraception. J. Clin. Endocrinol. Metab.86, 3188–3196 (2001).
   PubMed Web of Science ®Google Scholar
• Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J. Intern. Med. Suppl.738, 1–60 (1996).
   PubMedGoogle Scholar
• Escobar-Morreale H, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinylestradiol–desogestrel has beneficial effects on lipid profiles and improves insulin sensitivity. Fertil. Steril.74, 816–819 (2000).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Anconetani et al. The natural history of the metabolic syndrome in young women with polycystic ovary syndrome and the effect of long-term estrogen-progestogen treatment. Clin. Endocrinol.50, 517–527 (1999).
   PubMed Web of Science ®Google Scholar
• Korytkowski MT, Mokan M, Horwitz J, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.80, 3327–3334 (1995).
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab.82, 3074–3077 (1997).
   PubMed Web of Science ®Google Scholar
• Sharma ST,Wickham III EP, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endo. Prac.13(4), 373–379 (2007).
   Google Scholar
• Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled, cross-over trial. Hum. Reprod.22(11), 2967–2973 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356, 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Salley KES, Wickham EP, Chiang KI, Essah PA, Karjane NW, Nestler JE. Position statement: glucose intolerance in polycystic ovary sundrome – a position statement of the Androgen Excess Society. J. Clin. Endocrinol. Metab.92, 4546–4556 (2007).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Lopez-Bermejo A, del Rio L, Enriquez G, Valls C, de Zegher F. Combined low-dose pioglitazone, flutamide and metformin for women with androgen excess. J. Clin. Endocrinol. Metab.92, 1710–1714 (2007).
   PubMedGoogle Scholar
• Ibanez L, Valls C, Cabre S, de Zegher F. Flutamide–metformin plus ethinylestradiol–drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early low-dose flutamide. J. Clin. Endocrinol. Metab.89, 4716–4720 (2004).
   PubMedGoogle Scholar
• Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang XJ. Improving reproductive performance in overweight/obese women with effective weight management. Hum. Reprod. Update10, 267–280 (2004).
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz R, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med.353, 2111–2120 (2005).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome association with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab.90, 6364–6369 (2005).
   PubMed Web of Science ®Google Scholar
• Eid GM, Cottam DR, Velcu et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis.1(2), 77–80 (2005).
   PubMedGoogle Scholar
• Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med.357, 741–52 (2007).
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Pawelczyk L, Spaczynski RZ, Dzivra J, Dubela AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized cross-over trial. J. Clin. Endocrinol. Metab.92, 456–461 (2007).
   PubMed Web of Science ®Google Scholar
• Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J. Clin. Endocrinol. Metab.87, 1555–1559 (2002).
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Aregawi D, Winiorska M et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab.19, 831–842 (2006).
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril.77, 919–927 (2002).
   PubMed Web of Science ®Google Scholar
• Ibanez L, de Zegher F. Low dose flutamide-metformin therapy for hyperinsulinemic, hyperandrogenism in non-obese adolescents and women. Hum. Reprod. Update12, 242–252 (2006).
   Google Scholar
• Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol. Cell. Endocrinol.163, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Webber LJ, Stubbs S, Stark J et al. Formation and early development of follicles in the polycystic ovary syndrome. Lancet362, 1017–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans MC, Te Velde ER, Habea JDF, Fauser BCJM. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab.83, 2361–2365 (1998).
   PubMed Web of Science ®Google Scholar
• Santbrink RJ, Fauser BC. Ovulation induction in normogonadotropic anovulation (PCOS). Best Prac. Res. Clin. Endocrinol. Metab.20, 261–270 (2006).
   Google Scholar
• White DM, Polson DW, Kiddy et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab.81, 3821–3824 (1996).
   PubMed Web of Science ®Google Scholar
• Delbaere A, Smits G, Olatunbosun O, Pierson R, Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum. Reprod.19(3), 486–489 (2004).
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br. Med. J.327, 951–953 (2003).
   PubMed Web of Science ®Google Scholar
• Moll E, Bassuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomiphene citrate plus metformin and clomiphene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: a randomized double blind clinical trial. Br. Med. J.332, 1485–1488 (2006).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio Jr F, Falbo A et al. Prospective parallel randomized double-blind double dummy controlled clinical trial comparing clomiphene citrate and metformin as first line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 4068–4074 (2005).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio Jr F, Falbo A Russo T, Tolino A, Zullo F. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.92, 3498–3503 (2007).
   PubMed Web of Science ®Google Scholar
• Neveu N, Granger L, St Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil. Steril.87, 113–120 (2007).
   PubMed Web of Science ®Google Scholar
• Legro RS, Barnhart HX, Schlaff WD et al. Clomiphene, metformin or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med.356, 551–566 (2007).
   PubMed Web of Science ®Google Scholar
• Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum. Reprod. Update13(6), 527–537 (2007).
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J. Clin. Endocrinol. Metab.90, 60–65 (2005).
   PubMed Web of Science ®Google Scholar
• Rouzi AA, Ardawi MSM. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril.85, 428–435 (2006).
   PubMed Web of Science ®Google Scholar
• Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J. Clin. Endocrinol. Metab.91, 760–771 (2006).
   PubMed Web of Science ®Google Scholar
• Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil. Steril.86, 1447–1451 (2006).
   PubMed Web of Science ®Google Scholar
• Tulandi T, Martin J, Al-Fadhli R et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril.85, 1761–1765 (2006).
   PubMed Web of Science ®Google Scholar
• Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethasone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum. Reprod.21(7), 1805–1808 (2006).
   PubMed Web of Science ®Google Scholar
• Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycytic ovary syndrome. Cochrane Database Syst. Rev.3, CD001122 (2007).
   Google Scholar
• Palomba S, Zollo F, Diamanti-Kandarakis E, Orio F Jr. Surgery and laser diathermy. In: Insulin Resistance and Polycystic Ovarian Syndrome. Diamanti-Kandarakis E, Nestler JE, Panidis D, Pasquale R (Eds). Humana Press, NJ, USA 33, 461–477 (2007)
   Google Scholar
• Palomba S, Orio F Jr, Nardo LG et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J. Clin. Endocrinol. Metab.89, 4801–4809 (2004).
   PubMed Web of Science ®Google Scholar
• Ibanez L, Lopez-Bermejo A, Callejo J et al. Plycystic ovaries in non-obese adolescents and young women with ovarian androgen excess: relation to prenatal growth. J. Clin. Endocrinol. Metab.93, 196–199 (2008).
   PubMedGoogle Scholar
• Nader S. Adrenarche and polycystic ovary syndrome: a tale of two hypotheses. J. Pediatr. Adolesc. Gynecol.20, 353–360 (2007).
   Google Scholar